Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 5/2007

01-05-2007 | Original Article

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination

Authors: Teresa Cabrera, Ester Lara, José M. Romero, Isabel Maleno, Luis M. Real, Francisco Ruiz-Cabello, Pedro Valero, Francisco M. Camacho, Federico Garrido

Published in: Cancer Immunology, Immunotherapy | Issue 5/2007

Login to get access

Abstract

Our knowledge of the mechanisms underlying tumor-specific immune response and tumor escape has considerably increased. HLA class I antigen defects remain an important tumor escape mechanism since they influence the interactions between tumor cells and specific T and NK cells in the course of malignant disease. We have studied here HLA class I expression in six subcutaneous metastases obtained from a melanoma patient immunized with an autologous melanoma cell vaccine (M-VAX). We report in this paper that HLA class I antigen expression on these metastatic lesions strongly correlated with the course of the disease. The three metastases that were partially regressing at the time of their excision showed a strong HLA class I expression, whereas the progressing ones showed a very weak or negative staining with most of the anti-HLA class I mAbs used. Real-time quantitative PCR of the samples obtained from microdissected tumor tissue revealed a significant difference in the mRNA levels of HLA-ABC heavy chain and β2m between the two types of metastases, i.e., lower levels in progressing metastases and high levels in regressing ones, confirming the immunohistological findings. This is, to our knowledge, the first report where the clinical outcome of different HLA class I positive and negative melanoma metastases can be clearly correlated with the regression and progression of the disease, respectively.
Literature
1.
go back to reference Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268CrossRefPubMed Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268CrossRefPubMed
2.
3.
go back to reference Coulie PG, van der Bruggen P (2003) T cell responses of vaccinated cancer patients. Curr Opin Immunol 15:131–137CrossRefPubMed Coulie PG, van der Bruggen P (2003) T cell responses of vaccinated cancer patients. Curr Opin Immunol 15:131–137CrossRefPubMed
4.
go back to reference Berd D (2004) M-VAX: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 3:521–527CrossRefPubMed Berd D (2004) M-VAX: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 3:521–527CrossRefPubMed
5.
go back to reference Marchand M, Brichard V, van Baren N, Coulie PG (2001) Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 1:497–510CrossRefPubMed Marchand M, Brichard V, van Baren N, Coulie PG (2001) Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 1:497–510CrossRefPubMed
6.
go back to reference Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G (2005) Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5:463–476CrossRefPubMed Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G (2005) Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5:463–476CrossRefPubMed
7.
go back to reference Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101(Supp12):14631–14638CrossRefPubMed Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101(Supp12):14631–14638CrossRefPubMed
8.
go back to reference Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor 1ymphocytes. Proc Natl Acad Sci USA 101(Supp12):14639–14645CrossRefPubMed Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor 1ymphocytes. Proc Natl Acad Sci USA 101(Supp12):14639–14645CrossRefPubMed
9.
go back to reference Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101(Supp12):14567–14571CrossRefPubMed Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101(Supp12):14567–14571CrossRefPubMed
10.
go back to reference Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H (2005) Phase I/II study of immunotherapy with T cell peptide epitopes in patients with stage IV me1anoma. Cancer Immunol Immunother 54:208–218CrossRefPubMed Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H (2005) Phase I/II study of immunotherapy with T cell peptide epitopes in patients with stage IV me1anoma. Cancer Immunol Immunother 54:208–218CrossRefPubMed
11.
go back to reference Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F (1988) Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 5:203–212PubMed Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F (1988) Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 5:203–212PubMed
12.
go back to reference Kageshita T, Ishihara T, Campoli M, Ferrone S (2005) Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65:419–428CrossRefPubMed Kageshita T, Ishihara T, Campoli M, Ferrone S (2005) Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65:419–428CrossRefPubMed
13.
go back to reference Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, López-Botet M, Duggan-Keen M. Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95CrossRefPubMed Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, López-Botet M, Duggan-Keen M. Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95CrossRefPubMed
14.
go back to reference Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520–529CrossRefPubMed Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520–529CrossRefPubMed
15.
go back to reference Mendez R, Serrano A, Jager E, Maleno I, Ruiz-Cabello F, Knuth A, Garrido F (2001) Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 57:508–519CrossRefPubMed Mendez R, Serrano A, Jager E, Maleno I, Ruiz-Cabello F, Knuth A, Garrido F (2001) Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 57:508–519CrossRefPubMed
16.
go back to reference Mendez R, Ruiz-Cabello F, Rodriguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F (2006) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother [Epub ahead of print] PMID: 16622680 Mendez R, Ruiz-Cabello F, Rodriguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F (2006) Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother [Epub ahead of print] PMID: 16622680
17.
go back to reference Maleno I, Cabrera CM, Cabrera T, López-Nevot MA, Collado A, Ferrón A, Garrido F (2004) Distribution of HLA class I phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244–253CrossRefPubMed Maleno I, Cabrera CM, Cabrera T, López-Nevot MA, Collado A, Ferrón A, Garrido F (2004) Distribution of HLA class I phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244–253CrossRefPubMed
18.
go back to reference Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807–839CrossRefPubMed Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807–839CrossRefPubMed
19.
go back to reference Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape-phenotypes. Nat Immunol 3:999–1005CrossRefPubMed Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape-phenotypes. Nat Immunol 3:999–1005CrossRefPubMed
21.
go back to reference Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 10:904–910 Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 10:904–910
22.
go back to reference Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer 94:243–251CrossRefPubMed Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer 94:243–251CrossRefPubMed
23.
go back to reference Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759–767CrossRefPubMed Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759–767CrossRefPubMed
24.
go back to reference Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66:6405–6411CrossRefPubMed Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66:6405–6411CrossRefPubMed
25.
go back to reference Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340–347CrossRefPubMed Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340–347CrossRefPubMed
26.
go back to reference Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100–108CrossRefPubMed Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100–108CrossRefPubMed
27.
go back to reference Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109–119CrossRefPubMed Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109–119CrossRefPubMed
28.
go back to reference Griffioen M, Ouwerkerk IJ, Harten V, Schrier PI (2000) HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site. Immunogenetics 52:121–128CrossRefPubMed Griffioen M, Ouwerkerk IJ, Harten V, Schrier PI (2000) HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site. Immunogenetics 52:121–128CrossRefPubMed
29.
go back to reference Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117:248–255CrossRefPubMed Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117:248–255CrossRefPubMed
30.
go back to reference Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118:6–10CrossRefPubMed Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118:6–10CrossRefPubMed
31.
go back to reference Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G (2002) Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction. Immunol Rev 188:97–113CrossRefPubMed Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G (2002) Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction. Immunol Rev 188:97–113CrossRefPubMed
Metadata
Title
HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination
Authors
Teresa Cabrera
Ester Lara
José M. Romero
Isabel Maleno
Luis M. Real
Francisco Ruiz-Cabello
Pedro Valero
Francisco M. Camacho
Federico Garrido
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0226-7

Other articles of this Issue 5/2007

Cancer Immunology, Immunotherapy 5/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine